- BNF:
- 8.1.3
- Status:
- Red
- Decision Date:
- September 2016
Comments
RED 1,2,3: NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin.
(NHSE is the responsible commissioner for this drug. From August 2016 Pemetrexed will be available through routine commissioning).
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again